产妇接种疫苗后脐血中检测到针对 SARS-CoV-2 的新生儿抗体——病例报告。

Newborn antibodies to SARS-CoV-2 detected in cord blood after maternal vaccination - a case report.

机构信息

Florida Atlantic University - Charles E. Schmidt College of Medicine, 777 Glades Road BC-71, Boca Raton, FL, 33431, USA.

, Boca Raton, USA.

出版信息

BMC Pediatr. 2021 Mar 22;21(1):138. doi: 10.1186/s12887-021-02618-y.

Abstract

BACKGROUND

Maternal vaccination for Influenza and Tetanus, Diphtheria, acellular Pertussis (TDaP) have been well studied in terms of safety and efficacy for protection of the newborn by placental passage of antibodies. Similar newborn protection would be expected after maternal vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for coronavirus disease 2019 (COVID-19). There is a significant and urgent need for research regarding safety and efficacy of vaccination against SARS-CoV-2 during pregnancy.

CASE PRESENTATION

A vigorous, healthy, full-term female was born to a COVID-19 naïve mother who had received a single dose of messenger RNA (mRNA) vaccine for SARS-CoV-2 3 weeks prior to delivery. IgG cord blood antibodies were detected to SARS-CoV-2 at the time of birth.

CONCLUSION

Here, we report the first known case of an infant with SARS-CoV-2 IgG antibodies detectable in cord blood after maternal vaccination.

摘要

背景

母体接种流感疫苗和破伤风、白喉、无细胞百日咳(Tdap)在通过胎盘传递抗体来保护新生儿方面的安全性和有效性已得到充分研究。母体接种严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)疫苗后,预计也会对新生儿产生类似的保护作用,SARS-CoV-2 是导致 2019 年冠状病毒病(COVID-19)的病毒。迫切需要对 COVID-19 大流行期间孕妇接种 SARS-CoV-2 疫苗的安全性和有效性进行研究。

病例介绍

一位健康、足月的女婴出生,其母亲在分娩前 3 周接种了一剂信使 RNA(mRNA)疫苗以预防 SARS-CoV-2。在出生时检测到 SARS-CoV-2 的 IgG 脐血抗体。

结论

在这里,我们报告了首例已知的母亲接种 SARS-CoV-2 疫苗后在脐血中可检测到 SARS-CoV-2 IgG 抗体的婴儿病例。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索